Page 26 - Read Online

Page 218 Wu et al. Cancer Drug Resist 2018;1:204-18 I http://dx.doi.org/10.20517/cdr.2018.16

76. Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, et al. Cantuzumab mertansine in a three-times a week schedule: a phase I and
pharmacokinetic study. Cancer Chemother Pharmacol 2008;62:911-9.
77. Shapiro GI, Vaishampayan UN, LoRusso P, Barton J, Hua S, et al. First-in-human trial of an anti-5T4 antibody-monomethylauristatin
conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs 2017;35:315-23.
78. Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with
gastric cancer. Anticancer Res 2002;22:1033-8.
79. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J
Gynecol Cancer 1995;5:269-74.
80. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, et al. Prognostic significance of 5T4 oncofetal antigen expression in
colorectal carcinoma. Br J Cancer 1994;69:899-902.
81. Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, et al. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal
antigen expressed on tumor-initiating cells. Cancer Res 2011;71:4236-46.
82. Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, et al. Long-term tumor regression induced by an antibody-drug conjugate that
targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 2013;12:38-47.
83. Mao S, Garcia A, Chen T, Chaerkady R, Marreno A, et al. Abstract 2064: tumor cells treated with a PBD-based antibody-drug conjugate
targeting 5T4 develop acquired resistance due to 5T4 down-regulation and response to alternate therapeutics. Cancer Res 2017; doi:
10.1158/1538-7445.
84. Stern PL, Harrop R. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother
2017;66:415-26.
85. Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, et al. A randomized phase II non-comparative study of PF-04691502 and
gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol 2016;142:62-9.
86. Shor B, Kahler J, Dougher M, Xu J, Mack M, et al. Enhanced antitumor activity of an anti-5T4 antibody-drug conjugate in combination
with PI3K/mTOR inhibitors or taxanes. Clin Cancer Res 2016;22:383-94.
87. Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer
2018;118:312-24.
88. Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly
susceptible to CTLA-4/PD-1 blockade. Sci Transl Med 2015;7:315ra188.
89. Mignot F, Ajgal Z, Xu H, Geraud A, Chen JY, et al. Concurrent administration of anti-HER2 therapy and radiotherapy: systematic
review. Radiother Oncol 2017;124:190-9.
90. Henry KE, Ulaner GA, Lewis JS. Human epidermal growth factor receptor 2-targeted PET/single-photon emission computed
tomography imaging of breast cancer: noninvasive measurement of a biomarker integral to tumor treatment and prognosis. PET Clin
2017;12:269-88.